Allogene Therapeutics ALLO Operating Lease Liability Payments - 2027 (Lessee)

Operating Lease Liability Payments - 2027 (Lessee) at other companies

PrecigenPGEN

——

Immix Biopharma, Inc.IMMX

——

Artiva Biotherapeutics, Inc.ARTV

——

Other financials

Income statement

See full

Revenue-—

Operating income-$46.1M+29.3%

Net income-$42.6M+28.7%

EPS (diluted)-$0.18+35.7%

Balance sheet

See full

Cash & equivalents$40.6M-23.0%

Total debt$81.1M-8.9%

Total equity$278.9M-27.6%

Total assets$396.0M-22.1%

Cash flow

See full

Operating cash flow-$12.9M+75.6%

CapEx$9.0K-90.9%

Free cash flow-$12.9M+75.6%

Valuation

See full

Market cap$711.02M+164%

Enterprise value$751.47M+146%

Profitability

See full

Operating margin-1,241,813.6%-2,018,140pp

Net margin-1,170,863.6%-2,007,890pp

FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full

Return on equity-52.3%-5.7pp

Debt / equity0.3×+0.1×

Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's operating lease liability payments - 2027 (lessee).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Allogene Therapeutics's operating lease liability payments - 2027 (lessee)?: Allogene Therapeutics (ALLO) reported operating lease liability payments - 2027 (lessee) of $15.44M in Q1 2026.
How has Allogene Therapeutics's operating lease liability payments - 2027 (lessee) changed year-over-year?: Allogene Therapeutics's operating lease liability payments - 2027 (lessee) increased by 9.6% year-over-year, from $14.08M to $15.44M.